Figure 2 | Scientific Reports

Figure 2

From: First pan-specific vNAR against human TGF-β as a potential therapeutic application: in silico modeling assessment

Figure 2

Nucleotide and aminoacidic sequences of the vNAR T1. (a) Nucleotide and aminoacidic sequences of vNAR T1. (b) Multiple Sequence Alignment (MSA) of vNAR T1 domain with other vNAR sequences (GenBank AF336089, AF336087; AF336088; AY069988; AF336094), showing a long CDR3 (24 aa) of the vNAR T1 with recognition capacity against rhTGF-β. The CDR1 region is in an orange box. The CDR3 region is in a red box. The canonical cysteine residues (amino acids: 22 and 83) in FR1 and FR3 regions (highlighted in blue). The non-canonical cysteine residues in CDR1 and CDR3 regions (highlighted in yellow). (c) Structural analysis of vNAR T1 shows that the CDR3 region acts as a hairpin with the binding capacity of TGF-β isoforms (CDR3 region in a red box). (d) Ramachandran plot of the model shows 99 residues (96.1%) in favored regions and 4 residues (3.9%) in additional regions.

Back to article page